Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma

JAMA Oncology

Volumn 1, Issue 2, 2015, Pages 238-244

  Van Allen, Eliezer M ^a,b   Lui, Vivian W Y ^c,d   Egloff, Ann Marie ^d   Goetz, Eva M ^a   Li, Hua ^d   Johnson, Jonas T ^d   Duvvuri, Umamaheswar ^d   Bauman, Julie E ^d   Stransky, Nicolas ^e   Zeng, Yan ^d   Gilbert, Breean R ^d   Pendleton, Kelsey P ^d   Wang, Lin ^d   Chiosea, Simion ^d   Sougnez, Carrie ^b   Wagle, Nikhil ^a,b   Zhang, Fan ^f   Du, Yu ^d   Close, David ^g   Johnston, Paul A ^g   McKenna, Aaron ^h   Carter, Scott L ^b   Golub, Todd R ^a,b   Getz, Gad ^b,i   Mills, Gordon B ^f   Garraway, Levi A ^a,b   Grandis, Jennifer R ^d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Blueprint Medicines   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ANTAGONISTS AND INHIBITORS; BIOPSY; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CASE REPORT; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOADJUVANT THERAPY; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TIME FACTOR; TONGUE NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; ERLOTINIB HYDROCHLORIDE; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOLECULAR TARGETED THERAPY; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PHENOTYPE; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; TIME FACTORS; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84994493627     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.34     Document Type: Article

References (34)

1. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009;6(6):352-366.
2. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
3. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418-8424.
4. Kirby AM, A'Hern RP, D'Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006;94(5):631-636.
5. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980-1987.
6. Choe MS, Chen Z, Klass CM, Zhang X, Shin DM. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(10):3015-3023.
7. Klass CM, Choe MS, Hurwitz SJ, et al. Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. Head Neck. 2009;31(10):1263-1273.
8. Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2013;31(11):1405-1414.
9. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31(11):1415-1421.
10. Weber B, Sorensen BS, Knap MM, Madsen HH, Nexo E, Meldgaard P. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib. J Thorac Oncol. 2011;6(11):1946-1949.
11. Mody K, Strauss E, Lincer R, Frank RC. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer. 2010;10:570.
12. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.
13. Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-1433.
14. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546-553.
15. Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-1586.
16. Al-Ahmadie H, Iyer G, Hohl M, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014;4(9):1014-1021.
17. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8-15.
18. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20(6):682-688.
19. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
20. Arvind R, Shimamoto H, Momose F, Amagasa T, Omura K, Tsuchida N. A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation. Int J Oncol. 2005;27(6):1499-1504.
21. Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head Neck. 2012;34(9):1269-1276.
22. Psyrri A, Lee JW, Pectasides E, et al. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clin Cancer Res. 2014;20(11):3023-3032.
23. Hah JH, Zhao M, Pickering CR, et al. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck. 2014;36(11):1547-1554.
24. Young NR, Liu J, Pierce C, et al. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013;7(3):359-368.
25. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-1160.
26. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154-1157.
27. Dreszer TR, Karolchik D, Zweig AS, et al. The UCSC Genome Browser database: extensions and updates 2011. Nucleic Acids Res. 2012;40(Database issue):D918-D923.
28. Valiathan GM, Thenumgal SJ, Jayaraman B, et al. Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas. Asian Pac J Cancer Prev. 2012;13(12):6155-6157.
29. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576-582.
30. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371-375.
31. Mahalingam M, Arvind R, Ida H, Murugan AK, Yamaguchi M, Tsuchida N. ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila. Oncol Rep. 2008;20(4):957-962.
32. Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012;2(10):934-947.
33. Blanchet S, Ramgolam K, Baulig A, Marano F, Baeza-Squiban A. Fine particulate matter induces amphiregulin secretion by bronchial epithelial cells. Am J Respir Cell Mol Biol. 2004;30(4):421-427.
34. Yonesaka K, Zejnullahu K, Lindeman N, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008;14(21):6963-6973.